Financial toxicity and patient experience associated with financial burden of molecular-targeted and immune therapies for cancer: an observational study under public health insurance.
- DOI
- 10.1007/s10147-024-02479-2
- Published
- 2024 Apr
- Container
- International journal of clinical oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s10147-024-02479-2,
title = {Financial toxicity and patient experience associated with financial burden of molecular-targeted and immune therapies for cancer: an observational study under public health insurance.},
author = {Yamamoto S and Kondoh C and Nakagoshi H and Kakumen M and Yasuhara K and Nakai M and Kodani N and Sunda K and Higashide C and Katayama M and Arao H},
year = {2024},
journal = {International journal of clinical oncology},
doi = {10.1007/s10147-024-02479-2},
url = {https://doi.org/10.1007/s10147-024-02479-2}
}RIS
TY - JOUR TI - Financial toxicity and patient experience associated with financial burden of molecular-targeted and immune therapies for cancer: an observational study under public health insurance. AU - Yamamoto S AU - Kondoh C AU - Nakagoshi H AU - Kakumen M AU - Yasuhara K AU - Nakai M AU - Kodani N AU - Sunda K AU - Higashide C AU - Katayama M AU - Arao H PY - 2024 JO - International journal of clinical oncology DO - 10.1007/s10147-024-02479-2 UR - https://doi.org/10.1007/s10147-024-02479-2 ER -
APA
S, Y., C, K., H, N., M, K., K, Y., M, N., N, K., K, S., C, H., M, K., & H, A. (2024). Financial toxicity and patient experience associated with financial burden of molecular-targeted and immune therapies for cancer: an observational study under public health insurance.. International journal of clinical oncology. https://doi.org/10.1007/s10147-024-02479-2
Source records
- pubmed · retrieved 2026-09-26T08:52:11.026Z